Hanjoon Alex Kim - 04 Apr 2024 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)

Role
Chief Operating Officer
Signature
/s/ Hanjoon Alex Kim by Agnieszka Gallagher, Attorney-in-Fact
Issuer symbol
LAB
Transactions as of
04 Apr 2024
Net transactions value
$0
Form type
4
Filing time
05 Apr 2024, 18:58:09 UTC
Previous filing
06 Apr 2023
Next filing
21 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LAB Common Stock Options Exercise $0 +70,183 +100% $0.000000 140,366 04 Apr 2024 Direct
transaction LAB Common Stock Award $0 +70,702 +50% $0.000000 211,068 05 Apr 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LAB Restricted Stock Units Options Exercise $0 -70,183 -33% $0.000000 140,366 04 Apr 2024 Common Stock 70,183 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On April 11, 2023, the Reporting Person was granted a target amount of 77,185 performance-based restricted stock units ("RSUs") under the Issuer's 2011 Equity Incentive Plan, as amended. Each RSU represent the right, upon achievement of certain pre-established performance criteria, to receive one share of the Issuer's common stock, subject to vesting conditions. On April 5, 2024, the Board of Directors of the Issuer determined that certain of the RSU performance-based conditions were met resulting in the vesting of 70,702 RSUs as of March 31, 2024.
F2 Each RSU represents the contingent right to receive one share of the Issuer's common stock.
F3 On April 4, 2022, the Reporting Person was granted 280,732 RSUs, vesting in four equal annual installments beginning on April 4, 2023.